CAN:s bibliotek

*000      am a        a
*00118074
*007cr |||||||||||
*008070120s1992||||xxu||||es|||||||||1|eng||
*020  $a0-16-037914-8
*24510$aBioavailability of drugs to the brain and the blood-brain barrier.
*260  $aRockville, Md :$bNational Institute on Drug Abuse,$c1992
*300  $a265 s :$bill.
*440  $aNIDA research monograph series ;$v120 DHHS publication ; 92-1910
*500  $aE-bok
*520  $aThe basic neurobiology of addiction. Some relationships between addiction and drug delivery to the brain. Neuroactive peptides and amino acids at the blood-brain barrier: possible implications for drug abuse. MPTP toxicity and the "biochemical" blood-brain barrier. An overview of the multiple functions of the blood-brain barrier. Formation and differentiation of the brain capillaries. Nonpermeable and permeable vessels of the brain. The blood-brain barrier is not a "barrier" for many drugs. Drug delivery to the brain: barrier modification and drug modification methodologies. Cultured brain microvessel endothelial cells as in vitro models of the blood-brain barrier. Opioid peptide drug development: transport of opioid chimeric peptides through the blood-brain barrier. Redox approaches to drug delivery to the central nervous system. Drug delivery to the brain using and anti-transferrin receptor antibody. Permeation of the blood-brain barrier for drug delivery to the brain. Pathways into, through, and around the fluid-brain barriers
*650 4$aNeurobiology
*650 4$aSubstance abuse
*650 4$aDrugs
*650 4$aBiological availability
*650 4$aDrug administration routes
*650 4$aBrain
*650 4$aBlood-brain barrier
*650 4$a1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
*653  $aBiokemi
*653  $aBeroende
*653  $aHjärnan
*653  $aFarmakologi
*7001 $aFrankenheim, Jerry$eed.
*7001 $aBrown, Roger M.$eed.
*7101 $aNational Institute on Drug Abuse$0124050
*85640$uhttps://archives.drugabuse.gov/sites/default/files/monograph120.pdf
^